Posts by Author: Tom Lazenby

Clinical Trial Vendor Management presents challenges that are complex, at the core of this, data emerges, offering clarity and direction. As we continue into the final segment of our Fire Triangle blog post series, it’s time to dive into the role data plays in robust vendor management strategies. Every decision, strategy and every outcome hinges […]

In Clinical Trial Vendor Management, communication is the oxygen, facilitating every process and enabling a seamless flow of data. Diving into the Fire Triangle’s second pillar, let’s explore the importance of effective Communication, focusing on its three primary components: Escalation, Expectations, and change management. Escalation Escalation management acts is a safety net within the clinical […]

The intricacies of Clinical Trial Vendor Management are woven into a series of processes, these processes are managed and delivered by different people within the organisation and are often performed simultaneously in multi-disciplinary teams, so how do we ensure consistency and quality in delivery of the process? Errors in conduct of these processes throughout the […]

Managing vendors in clinical trials is a fine balance of several critical elements. For many in the industry, understanding these elements’ significance and interplay can be complex. That’s where the analogy of the Fire Triangle comes in handy. Just as fire needs oxygen, heat, and fuel to ignite, robust vendor management in clinical trials depends […]

Clinical trials, come with their own unique set of regulatory challenges. This is a technical challenge when navigating vendor management and oversight. As with many challenges with moving parts, the devil is often in the details. In this blog post we’ll hit on four of these challenges and offer insight into how clinical quality, clinical […]

Welcome back to the concluding part of our three-part series, “Risk Management Frameworks for Vendor Risk Management.” In [Part 1] we introduced you to fundamental risk management methodologies like flowcharts, check sheets, process mapping, cause and effect diagrams, and Failure Mode Effects Analysis (FMEA). [Part 2] delved into more advanced techniques such as Failure Mode, […]

Welcome to Part 2 of our three-part blog series, “Tools and Frameworks for Vendor Risk Management.” [Part 1] explored fundamental risk management methodologies, including flowcharts, check sheets, process mapping, cause and effect diagrams, and Failure Mode Effects Analysis (FMEA). In Part 2, you will learn about some more advanced risk management techniques, introducing: We will […]

This is a three-part blog series, “Tools and Frameworks for Vendor Risk Management,” where you will learn or be reacquainted with various risk management methodologies that can be employed to manage and mitigate risks associated with vendors in clinical trials. The series is designed to help you understand What, Why, When, and How these methodologies […]

Robust oversight of the delegated regulatory responsibilities in clinical trials is a challenge. Sponsors are outsourcing more of their clinical operations to vendors, the dynamics of responsibility and oversight becomes complex. When outsourced responsibilities are not managed properly, this process leads to a range of issues, from quality concerns and inspection findings to significant delays […]

Sponsor oversight of vendor management is a critical aspect that requires attention, especially when dealing with subcontractors. For clinical trial Sponsor organisations, managing subcontractors used by the primary vendor can be complex and filled with challenges. This blog post aims to shed light on how to optimise this process from preparation to closeout. The Importance […]